In recent years, GLP-1 receptor agonists have shifted from niche diabetes treatments to mainstream solutions for obesity, metabolic health, and even performance optimization
The Phase 2 data is genuinely impressive 24% body weight reduction over 48 weeks, with a safety profile broadly consistent with approved GLP-1 therapies, is a meaningful advance over anything currently on the market
Semaglutide's strength is depth of outcomes evidence: SELECT cardiovascular data, FLOW kidney protection, MASH approval (ESSENCE), and oral formulations
The core difference is that Mounjaro is the first medication to act on two hormonal receptors simultaneously (GIP and GLP-1), rather than just one
This case series provides patient-level data that complement the findings of a meta-analysis by He et al of the association of cholecystitis with GLP-1 receptor agonists, the researchers wrote